Presentation TCT 2024 TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus Presenter: Daria Feshchenko October 28, 2024
Presentation TCT 2024 TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation Presenter: Karl Fengler October 28, 2024
Presentation TCT 2024 TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program Presenter: Felix Mahfoud October 28, 2024
Presentation TCT 2024 TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program Presenter: Felix Mahfoud October 28, 2024
News Conference News ESC 2024 New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower Yael L. Maxwell September 04, 2024
News Daily News Study Supports Cost-effectiveness of Renal Denervation for Hypertension Todd Neale August 23, 2024
News Daily News Hypertension Expert George Bakris Mourned by Colleagues and Friends L.A. McKeown June 18, 2024
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
Presentation ACC 2024 Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial Presenter: David E. Kandzari April 08, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Daily News Top Policy and Practice News for Cardiologists in 2023 Caitlin E. Cox December 20, 2023
Presentation Controversies and Advances 2023 Renal Denervation Will Be an Option for Most Hypertensive Patients! Presenter: Michael J. Bloch November 30, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2023 Shelley Wood November 30, 2023
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Daily News FDA Approves Paradise Renal Denervation System: What Comes Next? Todd Neale November 08, 2023
News Conference News TCT 2023 RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months Todd Neale October 31, 2023
Presentation TCT 2023 TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials Presenter: Michael Bloch October 25, 2023